Saturn V Capital Management LP
CIK: 0001964437Latest portfolio: $544.9M · Q4 2025
Holdings
20
Total Value
$544.9M
New Positions
8
Closed Positions
5
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ABVXABIVAX SA | 649,179 | $87.5M | 16.07% | -152,045 | |
| 2 | AMLXAMYLYX PHARMACEUTICALS INC | 4,496,487 | $54.3M | 9.97% | -108,391 | |
| 3 | COGTCOGENT BIOSCIENCES INC | 1,217,064 | $43.2M | 7.93% | -807,977 | |
| 4 | JAZZJAZZ PHARMACEUTICALS PLC | 248,070 | $42.2M | 7.74% | -52,540 | |
| 5 | PCVXVAXCYTE INC | 798,940 | $36.9M | 6.77% | +10K | |
| 6 | DYNDYNE THERAPEUTICS INC | 1,788,616 | $35.0M | 6.42% | -885,853 | |
| 7 | PHVSPHARVARIS N V | 1,140,033 | $31.6M | 5.81% | +254K | |
| 8 | CELCCELCUITY INC | 317,095 | $31.6M | 5.80% | -156,733 | |
| 9 | ALMSALUMIS INC | 3,135,953 | $30.6M | 5.62% | NEW | |
| 10 | IRONDISC MEDICINE INC | 298,429 | $23.7M | 4.35% | -42,468 | |
| 11 | XFORX4 PHARMACEUTICALS INC | 5,800,530 | $23.2M | 4.26% | NEW | |
| 12 | MNPRMONOPAR THERAPEUTICS INC | 325,701 | $21.3M | 3.90% | +170K | |
| 13 | IVVDINVIVYD INC | 7,735,386 | $19.1M | 3.51% | NEW | |
| 14 | OCULOCULAR THERAPEUTIX INC | 1,504,880 | $18.3M | 3.35% | +353K | |
| 15 | IMMXIMMIX BIOPHARMA INC | 2,999,169 | $15.7M | 2.88% | NEW | |
| 16 | OCSOCULIS HOLDING AG | 516,761 | $10.3M | 1.89% | NEW | |
| 17 | IKTINHIBIKASE THERAPEUTICS INC | 3,856,799 | $7.9M | 1.45% | NEW | |
| 18 | CNTACENTESSA PHARMACEUTICALS PLC | 282,692 | $7.1M | 1.30% | -451,847 | |
| 19 | OVIDOVID THERAPEUTICS INC | 2,500,000 | $4.1M | 0.75% | NEW | |
| 20 | IVAINVENTIVA SA | 283,166 | $1.3M | 0.24% | NEW |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare100.0% ($8.754554317432304e+86T)
Filing History
Fund Information
Saturn V Capital Management LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $544.9M across 20 holdings. The largest position is ABIVAX SA (ABVX), representing 16.1% of the portfolio. Compared to the previous quarter, the fund opened 8 new positions and closed 5 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.